Benazepril to Losartan Dose Conversion
When converting from benazepril to losartan, use a target dose of losartan 100 mg once daily if the patient was on benazepril 40 mg daily, or losartan 50 mg once daily if the patient was on benazepril 20 mg daily (50% of target dose). 1
Conversion Framework
The 2020 ACC/AHA guidelines provide clear target dosing for both ACE inhibitors and ARBs in heart failure with reduced ejection fraction, which serves as the framework for conversion 1:
Target Doses from Guidelines
Benazepril:
- Target dose: 40 mg once daily
- 50% of target: 20 mg once daily
Losartan:
- Target dose: 100 mg once daily (per FDA labeling; ACC/AHA recommends 150 mg but FDA max is 100 mg)
- 50% of target: 50 mg once daily
Practical Conversion Strategy
If patient is on benazepril 40 mg daily (target dose):
- Switch to losartan 100 mg once daily
- This represents equivalent target dosing for renin-angiotensin system inhibition
If patient is on benazepril 20 mg daily (50% of target):
- Switch to losartan 50 mg once daily
- Maintains equivalent proportional dosing
If patient is on benazepril 10 mg daily (25% of target):
- Switch to losartan 25-50 mg once daily
- Plan to uptitrate to at least 50 mg (50% of target) within 2 weeks if tolerated
Important Clinical Considerations
Dose-Response Evidence
The HEAAL trial demonstrated that losartan 150 mg daily was superior to 50 mg daily, with a 10% relative risk reduction in death or heart failure hospitalization 2, 3, 2. This underscores the importance of achieving higher doses when tolerated. Similarly, the ROAD study showed that uptitration of losartan to optimal antiproteinuric doses (median 100 mg, range 50-200 mg) resulted in 53% risk reduction for renal endpoints compared to conventional 50 mg dosing 4.
Titration Timeline
After conversion, adjust doses no more frequently than every 2 weeks to target doses or maximally tolerated doses 1. This allows adequate time to assess blood pressure response and monitor for adverse effects like hyperkalemia or renal dysfunction.
Monitoring Requirements
- Check blood pressure, serum potassium, and creatinine within 1-2 weeks after conversion
- Watch for symptomatic hypotension, particularly if patient is volume depleted
- Losartan produces similar rates of hyperkalemia and renal dysfunction as ACE inhibitors 5, 6
Key Differences Between Agents
Cough: Losartan causes significantly less cough than benazepril (8-fold reduction in CORD trials) 7. This is the most common reason for switching from an ACE inhibitor to an ARB.
Angioedema: While rare with losartan, cases have occurred in patients who previously had angioedema with ACE inhibitors 5, 6. Exercise extreme caution and counsel patients on warning signs.
Efficacy equivalence: Multiple studies show comparable blood pressure reduction and metabolic effects between benazepril and losartan 7, 8, 9. The VALIANT trial demonstrated valsartan was non-inferior to captopril, supporting ARB use as an alternative to ACE inhibitors 2, 3.
Special Populations
Renal impairment: No dose adjustment needed unless patient is volume depleted 10, 11
Hepatic impairment: Start losartan at 25 mg daily in mild-to-moderate hepatic dysfunction 11
Black patients: The LIFE study showed Black patients had better outcomes with atenolol than losartan for cardiovascular endpoints, though blood pressure reduction was similar 11. Consider this when converting in Black patients with left ventricular hypertrophy.
Common Pitfall
Do not assume 1:1 mg equivalence between benazepril and losartan. The conversion is based on achieving equivalent target doses proven effective in clinical trials, not on milligram-to-milligram pharmacologic potency. A patient on benazepril 10 mg should not simply receive losartan 10 mg—this would be a subtherapeutic dose.